Johnson & Johnson (N:JNJ)

Sector:  Healthcare Industry:  Pharmaceuticals
 
See Regulatory Filings on SEC
Company Contact
Address: One Johnson & Johnson Plaza
NEW BRUNSWICK NJ 08933
Tel: 1-800-9505089
Website: https://www.jnj.com
IR: See website
<
Key People
Joaquin Boix Duato
Chairman of the Board, Chief Executive Officer
Tim Schmid
Executive Vice President, Worldwide Chairman of MedTech
Joseph J. Wolk
Chief Financial Officer, Executive Vice President
Peter M. Fasolo
Chief Human Resource Officer, Executive Vice President
Kathryn E. Wengel
Executive Vice President, Chief Technology Officer and Risk Officer
James Swanson
Executive Vice President, Chief Information Officer
Elizabeth Forminard
Executive Vice President, General Counsel
Vanessa Broadhurst
Executive Vice President - Global Corporate Affairs
William N. Hait
Executive Vice President, Chief External Innovation and Medical Officer
John C. Reed
Executive Vice President - Innovative Medicine, Research and Development
   
Business Overview
Johnson & Johnson, through its subsidiaries, is engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company's primary focus is products related to human health and well-being. It operates through two segments: Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. Products in this segment are distributed directly to retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment includes a broad portfolio of products used in the orthopedic, surgery, interventional solutions, and vision fields. These products are distributed to wholesalers, hospitals, and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics.
Financial Overview
For the fiscal year ended 31 December 2023, Johnson & Johnson revenues increased 6% to $85.16B. Net income before extraordinary items decreased 19% to $13.33B. Revenues reflect MedTech segment increase of 11% to $30.4B, Innovative Medicine segment increase of 4% to $54.76B, United States segment increase of 11% to $46.44B, International segment increase of 2% to $38.72B.
Employees: 131,900 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $387,054M as of Dec 31, 2023
Annual revenue (TTM): $85,159M as of Dec 31, 2023
EBITDA (TTM): $30,987M as of Dec 31, 2023
Net annual income (TTM): $13,326M as of Dec 31, 2023
Free cash flow (TTM): $6,478M as of Dec 31, 2023
Net Debt Last Fiscal Year: $6,405M as of Dec 31, 2023
Shares outstanding: 2,409,783,054 as of Feb 27, 2024
Index Membership: S&P 500, Dow Industry
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.